This article is sponsored by Johnson & Johnson. | Explore a quadruplet treatment regimen now approved for newly diagnosed multiple myeloma patients who are transplant ineligible.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple…
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to…
Due to advances in cancer treatment and early detection, the population of cancer survivors continues to grow, reaching more than
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3…
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are…
